Sander Slootweg currently serves on the boards of Forbion’s portfolio companies Xention Discovery Ltd, Provesica Ltd, Pulmagen Therapeutics, Ltd, Oxyrane Ltd and uniQure. In addition, Sander was responsible for two of Forbion’s recent exits: Biovex, Inc. sold to Amgen for up to USD 1 billion and Fovea Pharmaceutics SA sold to Sanofi-aventis for up to EUR 390 million.

Previously, Sander was an Investment Director at ABN AMRO Capital Life Sciences. Other activities at ABN AMRO included buy-out/ growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami).